Report of Foreign Issuer (6-k)
August 11 2020 - 8:22AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of August 2020
Commission
File Number: 001-37643
KITOV
PHARMA LTD.
(Translation
of registrant’s name into English)
One
Azrieli Center, Round Tower, Tel Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On
August 11, 2020, Kitov Pharma Ltd. (the “Company” or the “Registrant”) issued a press release, “Kitov
Pharma Provides Corporate Update and Reports First Half 2020 Financial Results.” A copy of this press release, together
with the Company’s Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2020, and for the six months
then ended, are furnished herewith as Exhibits 99.1 and 99.2, respectively.
Exhibits
Incorporation
by Reference
This
Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration
Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117
and 333-211477), the
Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s
Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s
Registration Statement on Form
F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195),
the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s
Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s
Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327), the Registrant’s
Registration Statement on Form
F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333- 238229), the Registrant’s
Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 28, 2020 (Registration file number 333-238481) and each of the
Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration
file numbers 333-239807
and 333-233793),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
KITOV PHARMA LTD.
|
|
|
|
August 11, 2020
|
By:
|
/s/
Isaac Israel
|
|
|
Isaac Israel
|
|
|
CEO & Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024